bpc 157 peptide adverse effects BPC-157 BPC 157 in Australia: Benefits,
Description
The Australian Crime Commission said it had relied on information from ASADA in compiling its report on drugs in sport, which stated several times AOD-9604 was not prohibited
This is thought to maintain more stable levels of the peptide in the system
Despite headlines suggesting a ban, the FDA has simply placed BPC-157 in a category requiring further investigation
Across the six published trials, the most common adverse events were headache, mild gastrointestinal effects (diarrhea, flatulence, nausea), nasopharyngitis, fatigue, dizziness, and mild injection-site reactions
